BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 34581433)

  • 61. [Ibrutinib therapy for a blastoid variant mantle cell lymphoma patient with early extranodal relapse after autologous stem cell transplantation].
    Nakamura K; Saburi M; Kondo Y; Soga Y; Itani K; Kohno K; Otsuka M; Nakayama T
    Rinsho Ketsueki; 2019; 60(12):1663-1668. PubMed ID: 31902818
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Long-term clinical and molecular remissions in patients with mantle cell lymphoma following high-dose therapy and autologous stem cell transplantation.
    Metzner B; Müller TH; Gebauer W; Casper J; Kraemer D; Rosien B; Schumann-Binarsch S; Thole R; Köhne CH; Dreyling M; Hoster E; Pott C
    Ann Hematol; 2014 May; 93(5):803-10. PubMed ID: 24337447
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Early lymphocyte recovery after autologous stem cell transplantation predicts superior survival in mantle-cell lymphoma.
    Joao C; Porrata LF; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Gastineau DA; Markovic SN
    Bone Marrow Transplant; 2006 May; 37(9):865-71. PubMed ID: 16532015
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Treatment for mantle cell lymphoma].
    Izutsu K
    Rinsho Ketsueki; 2017; 58(10):2026-2032. PubMed ID: 28978845
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Autologous Stem Cell Transplant: Still the Standard for Fit Patients With Mantle Cell Lymphoma.
    Staton AD; Langston AA
    Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S96-S99. PubMed ID: 28760309
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation.
    Chen RW; Palmer JM; Tomassetti S; Popplewell LL; Alluin J; Chomchan P; Nademanee AP; Siddiqi T; Tsai NC; Chen L; Zuo F; Abary R; Cai JL; Herrera AF; Rossi JJ; Rosen ST; Forman SJ; Kwak LW; Holmberg LA
    J Hematol Oncol; 2018 Jun; 11(1):87. PubMed ID: 29954415
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries.
    Vandenberghe E; Ruiz de Elvira C; Loberiza FR; Conde E; López-Guillermo A; Gisselbrecht C; Guilhot F; Vose JM; van Biesen K; Rizzo JD; Weisenburger DD; Isaacson P; Horowitz MM; Goldstone AH; Lazarus HM; Schmitz N
    Br J Haematol; 2003 Mar; 120(5):793-800. PubMed ID: 12614212
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Experiences with Glofitamab Administration following CAR T Therapy in Patients with Relapsed Mantle Cell Lymphoma.
    Heini AD; Bacher U; Porret N; Wiedemann G; Legros M; Stalder Zeerleder D; Seipel K; Novak U; Daskalakis M; Pabst T
    Cells; 2022 Sep; 11(17):. PubMed ID: 36078155
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma.
    Le Gouill S; Thieblemont C; Oberic L; Moreau A; Bouabdallah K; Dartigeas C; Damaj G; Gastinne T; Ribrag V; Feugier P; Casasnovas O; Zerazhi H; Haioun C; Maisonneuve H; Houot R; Jardin F; Van Den Neste E; Tournilhac O; Le Dû K; Morschhauser F; Cartron G; Fornecker LM; Canioni D; Callanan M; Béné MC; Salles G; Tilly H; Lamy T; Gressin R; Hermine O;
    N Engl J Med; 2017 Sep; 377(13):1250-1260. PubMed ID: 28953447
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality.
    Fenske TS; Zhang MJ; Carreras J; Ayala E; Burns LJ; Cashen A; Costa LJ; Freytes CO; Gale RP; Hamadani M; Holmberg LA; Inwards DJ; Lazarus HM; Maziarz RT; Munker R; Perales MA; Rizzieri DA; Schouten HC; Smith SM; Waller EK; Wirk BM; Laport GG; Maloney DG; Montoto S; Hari PN
    J Clin Oncol; 2014 Feb; 32(4):273-81. PubMed ID: 24344210
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC.
    Touzeau C; Leux C; Bouabdallah R; Roussel M; Delarue R; Bouabdallah K; Thieblemont C; Cacheux V; Cartron G; Compain L; Gyan E; Morschhauser F; Casasnovas O; Moles MP; Michallet AS; Gressin R; Damaj G; Rose C; Sirvent A; Hermine O; Mohty M; Milpied N; Le Gouill S
    Ann Hematol; 2014 Feb; 93(2):233-42. PubMed ID: 24563925
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC.
    Touzeau C; Leux C; Bouabdallah R; Roussel M; Delarue R; Bouabdallah K; Thieblemont C; Cacheux V; Cartron G; Compain L; Gyan E; Morschhauser F; Casasnovas O; Moles MP; Michallet AS; Gressin R; Damaj G; Rose C; Sirvent A; Hermine O; Mohty M; Milpied N; Le Gouill S
    Ann Hematol; 2014 Feb; 93(2):233-42. PubMed ID: 23949376
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study.
    Abrahamsson A; Albertsson-Lindblad A; Brown PN; Baumgartner-Wennerholm S; Pedersen LM; D'Amore F; Nilsson-Ehle H; Jensen P; Pedersen M; Geisler CH; Jerkeman M
    Blood; 2014 Aug; 124(8):1288-95. PubMed ID: 24859361
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial.
    Ladetto M; Cortelazzo S; Ferrero S; Evangelista A; Mian M; Tavarozzi R; Zanni M; Cavallo F; Di Rocco A; Stefoni V; Pagani C; Re A; Chiappella A; Balzarotti M; Zilioli VR; Gomes da Silva M; Arcaini L; Molinari AL; Ballerini F; Ferreri AJM; Puccini B; Benedetti F; Stefani PM; Narni F; Casaroli I; Stelitano C; Ciccone G; Vitolo U; Martelli M
    Lancet Haematol; 2021 Jan; 8(1):e34-e44. PubMed ID: 33357480
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Survival of Lymphoma Patients Experiencing Relapse or Progression after an Allogeneic Hematopoietic Cell Transplantation.
    Epperla N; Hamadani M; Ahn KW; He F; Kodali D; Kleman A; Hari PN; Pasquini M; Fenske TS; Craig MD; Kanate AS; Bachanova V
    Biol Blood Marrow Transplant; 2018 May; 24(5):983-988. PubMed ID: 29410340
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype.
    Bernard M; Gressin R; Lefrère F; Drénou B; Branger B; Caulet-Maugendre S; Tass P; Brousse N; Valensi F; Milpied N; Voilat L; Sadoun A; Ghandour C; Hunault M; Leloup R; Mannone L; Hermine O; Lamy T
    Leukemia; 2001 Nov; 15(11):1785-91. PubMed ID: 11681422
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Paramount therapy for young and fit patients with mantle cell lymphoma: strategies for front-line therapy.
    Ye H; Desai A; Huang S; Jung D; Champlin R; Zeng D; Yan F; Nomie K; Romaguera J; Ahmed M; Wang ML
    J Exp Clin Cancer Res; 2018 Jul; 37(1):150. PubMed ID: 30005678
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Autologous stem cell transplantation in patients with mantle cell lymphoma.
    Oinonen R; Jantunen E; Itälä M; Lehtinen T; Kuittinen O; Franssila K; Wiklund T; Elonen E
    Leuk Lymphoma; 2002 Jun; 43(6):1229-37. PubMed ID: 12152990
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Autotransplantation for mantle cell lymphoma.
    Vose JM
    Cancer J; 2012; 18(5):427-31. PubMed ID: 23006947
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Allogeneic stem cell transplantation for mantle cell lymphoma-update of the prospective trials of the East German Study Group Hematology/Oncology (OSHO#60 and #74).
    Krüger WH; Hirt C; Basara N; Sayer HG; Behre G; Fischer T; Grobe N; Maschmeyer G; Neumann T; Schneidewind L; Niederwieser D; Dölken G; Schmidt CA
    Ann Hematol; 2021 Jun; 100(6):1569-1577. PubMed ID: 33829299
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.